Kairos Pharma将在2025年ESMO大会上展示其前列腺癌二期临床试验取得的积极安全性和疗效数据。
Kairos Pharma将在2025年ESMO大会上展示其前列腺癌二期临床试验取得的积极安全性和疗效数据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.